"The U.S. Food and Drug Administration today approved Liposorber LA-15 System to treat pediatric patients with primary focal segmental glomerulosclerosis (FSGS) either before transplant, or after renal (kidney) transplantation in which there is re"...
In clinical studies, patients have occasionally experienced nausea during PhosLo (calcium acetate tablet) therapy. Hypercalcemia may occur during treatment with PhosLo (calcium acetate tablet) . Mild hypercalcemia (Ca>10.5mg/dL) may be asymptomatic or manifest itself as constipation, anorexia, nausea and vomiting. More severe hypercalcemia (Ca>12mg/dl) is associated with confusion, delirium, stupor and coma. Mild hypercalcemia is easily controlled by reducing the PhosLo (calcium acetate tablet) dose or temporarily discontinuing therapy. Severe hypercalcemia can be treated by acute hemodialysis and discontinuing PhosLo (calcium acetate tablet) therapy. Decreasing dialysate calcium concentration could reduce the incidence and severity of PhosLo (calcium acetate tablet) induced hypercalcemia. The long-term effect of PhosLo (calcium acetate tablet) on the progression of vascular or soft-tissue calcification has not been determined.
Isolated cases of pruritus have been reported which may represent allergic reactions.
Read the Phoslo (calcium acetate tablet) Side Effects Center for a complete guide to possible side effects
Last reviewed on RxList: 5/27/2009
Additional Phoslo Information
Phoslo - User Reviews
Phoslo User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.